Literature DB >> 6199603

Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects.

R A Jensen, E M Acton, J H Peters.   

Abstract

We have evaluated the dose-, schedule-, and time-dependent effects of doxorubicin (DXR) on the rat electrocardiogram (ECG) and have related ECG alterations to cellular transmembrane potential (TMP) changes and ultrastructural changes in preparations isolated from DXR-treated animals. DXR was administered intraperitoneally at 1, 2, and 4 mg/kg (all five times per week) or 5 mg/kg once per week up to a cumulative dose of 20 mg/kg, or 2 mg/kg daily for 5 days for a cumulative dose of 10 mg/kg. Posttreatment deaths were due to acute toxicity (bone marrow suppression) or congestive cardiomyopathy (8-14 weeks after the end of dosing). The most consistent ECG changes observed with DXR treatment (greater than 10 mg/kg cumulative dose) were a reversible prolongation of the QRS complex and a progressive lengthening of the Q alpha T interval; changes in R-, S-, and T-wave voltages were more variable. ECG toxicity was more pronounced when the drug was given on a weekly schedule. On the cellular level, DXR treatment led to a decrease in Vmax, with a slight increase or no change in resting potential, and a marked prolongation in action potential duration at the 50% and 75% repolarization levels. The ECG and TMP changes were accompanied by ultrastructural changes that increased in severity during the posttreatment period. Our data further support the usefulness of the rat ECG in anthracycline cardiotoxicity studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199603

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  16 in total

1.  L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations.

Authors:  E C Keung; L Toll; M Ellis; R A Jensen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Acute hemodynamic effects of coronary artery ligation in conscious rats.

Authors:  R G Schoemaker; J Urquhart; J J Debets; H A Struyker Boudier; J F Smits
Journal:  Basic Res Cardiol       Date:  1990 Jan-Feb       Impact factor: 17.165

3.  Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.

Authors:  F Villani; M Galimberti; E Lanza; A Rozza; L Favalli; P Poggi
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

4.  Fructose-1,6-diphosphate reduces acute ECG changes due to doxorubicin in isolated rat heart.

Authors:  N Bernardini; R Danesi; M C Bernardini; M Del Tacca
Journal:  Experientia       Date:  1988-12-01

Review 5.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

Review 6.  Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Authors:  Kuan-Liang Liu; Jen-Shi Chen; Shin-Cheh Chen; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2013-07       Impact factor: 2.672

7.  Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.

Authors:  F Villani; M Galimberti; F Zunino; E Monti; A Rozza; E Lanza; L Favalli; P Poggi
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats.

Authors:  R Danesi; N Bernardini; A Marchetti; M Bernardini; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  The Protective Effects of Coenzyme Q10 and Lisinopril Against Doxorubicin-Induced Cardiotoxicity in Rats: A Stereological and Electrocardiogram Study.

Authors:  Maryam Rahmanifard; Mahmood Vessal; Ali Noorafshan; Saied Karbalay-Doust; Maryam Naseh
Journal:  Cardiovasc Toxicol       Date:  2021-08-02       Impact factor: 3.231

10.  Calreticulin-STAT3 signaling pathway modulates mitochondrial function in a rat model of furazolidone-induced dilated cardiomyopathy.

Authors:  Ming Zhang; Jin Wei; Hu Shan; Hao Wang; Yanhe Zhu; Jiahong Xue; Lin Lin; Rui Yan
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.